Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
Rhea-AI Summary
Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company focused on developing small molecule medicines for brain conditions, announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The conference is scheduled for July 29-30, 2025.
Positive
- None.
Negative
- None.
News Market Reaction 7 Alerts
On the day this news was published, OVID gained 4.65%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.4% during that session. Argus tracked a trough of -13.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $50M at that time.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, announced today that the Company’s management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Investor Relations
Victoria Fort
202-361-0445
VFort@ovidrx.com
FAQ
When is Ovid Therapeutics (OVID) participating in the BTIG Virtual Biotechnology Conference?
What is Ovid Therapeutics' (OVID) main business focus?
Where can investors access Ovid Therapeutics' (OVID) BTIG conference presentation?
What type of conference is OVID participating in?
